Literature DB >> 20659125

Interferon-α increases monocyte migration via platelet-monocyte interaction in murine intestinal microvessels.

M Higashiyama1, R Hokari, C Kurihara, T Ueda, M Nakamura, S Komoto, Y Okada, C Watanabe, A Kawaguchi, S Nagao, S Miura.   

Abstract

The aim of this study was to investigate the effect of interferon (IFN)-α on recruitment of platelets and monocytes within the murine small intestinal venular endothelium. Monocytes were isolated from bone marrow of C57B6 mice. Platelets were collected from murine blood. Rolling and adhesion to submucosal microvessels in the small intestine were examined under an intravital fluorescence microscope after injection of fluorescein-labelled monocytes or platelets. In some mice, IFN-α (5×10(5) U/kg) was administered intraperitoneally. After treatment with an antibody against P-selectin, changes in monocyte and platelet migration were also investigated. Changes in monocyte migration under the condition of thrombocytopenia were also investigated. Platelets and monocytes interacted with murine intestinal microvessels, although only few platelets and monocytes showed migration behaviour. Intraperitoneal injection of IFN-α enhanced the migration of both platelets and monocytes in the intestinal microvessels. Pretreatment with anti-P-selectin attenuated the increase in migration of platelets and monocytes induced by administration of IFN-α. Thrombocytopenia decreased the rolling ratio of monocytes, suggesting that the effect of IFN-α on migration was P-selectin-dependent, derived from both the endothelium of microvessels and platelets. The results of this study suggest that IFN-α acts as a potent proinflammatory agent via its stimulatory effect on the endothelium-platelet-monocyte interaction in intestinal microvessels by a P-selectin-dependent mechanism.
© 2010 The Authors. Clinical and Experimental Immunology © 2010 British Society for Immunology.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20659125      PMCID: PMC2990941          DOI: 10.1111/j.1365-2249.2010.04222.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  28 in total

1.  Phase II study of recombinant alpha interferon in the treatment of advanced non-small cell lung carcinoma.

Authors:  S M Grunberg; R A Kempf; L M Itri; C L Venturi; W D Boswell; M S Mitchell
Journal:  Cancer Treat Rep       Date:  1985-09

Review 2.  Cardiotoxicity of interferon. A review of 44 cases.

Authors:  M Sonnenblick; A Rosin
Journal:  Chest       Date:  1991-03       Impact factor: 9.410

Review 3.  Cytokine therapeutics: lessons from interferon alpha.

Authors:  J U Gutterman
Journal:  Proc Natl Acad Sci U S A       Date:  1994-02-15       Impact factor: 11.205

4.  Exacerbation of ulcerative colitis during alpha-interferon therapy for chronic hepatitis C.

Authors:  A Mitoro; M Yoshikawa; K Yamamoto; M Mimura; Y Yoshikawa; A Shiroi; T Mochi; T Sakamoto; J Yamao; E Kikuchi
Journal:  Intern Med       Date:  1993-04       Impact factor: 1.271

5.  Endotoxin stimulates monocyte-endothelial cell interactions in mouse intestinal Peyer's patches and villus mucosa.

Authors:  N Ishii; Y Tsuzuki; K Matsuzaki; J Miyazaki; Y Okada; R Hokari; A Kawaguchi; S Nagao; K Itoh; S Miura
Journal:  Clin Exp Immunol       Date:  2004-02       Impact factor: 4.330

6.  A randomised placebo controlled trial of pegylated interferon alpha in active ulcerative colitis.

Authors:  H Tilg; H Vogelsang; O Ludwiczek; H Lochs; A Kaser; J-F Colombel; H Ulmer; P Rutgeerts; S Krüger; A Cortot; G D'Haens; M Harrer; C Gasche; F Wrba; I Kuhn; W Reinisch
Journal:  Gut       Date:  2003-12       Impact factor: 23.059

7.  Prospective evaluation of interferon-alpha in treatment of chronic active Crohn's disease.

Authors:  C Gasché; W Reinisch; H Vogelsang; R Pötzi; E Markis; M Micksche; H P Wirth; A Gangl; H Lochs
Journal:  Dig Dis Sci       Date:  1995-04       Impact factor: 3.199

8.  A phase I study of recombinant interferon-alpha administered as a seven-day continuous venous infusion at circadian-rhythm modulated rate in patients with cancer.

Authors:  S Iacobelli; C Garufi; L Irtelli; M T Martino; F Santobuono; G Vicario; N Tinari; B Fiorentino; P Innocenti; C Natoli
Journal:  Am J Clin Oncol       Date:  1995-02       Impact factor: 2.339

9.  Interferon-associated retinopathy.

Authors:  D R Guyer; J Tiedeman; L A Yannuzzi; J S Slakter; D Parke; J Kelley; R A Tang; M Marmor; G Abrams; J W Miller
Journal:  Arch Ophthalmol       Date:  1993-03

Review 10.  Clinical toxicity of interferons in cancer patients: a review.

Authors:  J R Quesada; M Talpaz; A Rios; R Kurzrock; J U Gutterman
Journal:  J Clin Oncol       Date:  1986-02       Impact factor: 44.544

View more
  5 in total

Review 1.  Elucidation of monocyte/macrophage dynamics and function by intravital imaging.

Authors:  Rejane Rua; Dorian B McGavern
Journal:  J Leukoc Biol       Date:  2015-07-10       Impact factor: 4.962

Review 2.  Endothelial function and endothelial progenitor cells in systemic lupus erythematosus.

Authors:  Anselm Mak; Jerry Kok Yen Chan
Journal:  Nat Rev Rheumatol       Date:  2022-04-07       Impact factor: 20.543

3.  Type I interferons are associated with subclinical markers of cardiovascular disease in a cohort of systemic lupus erythematosus patients.

Authors:  Emily C Somers; Wenpu Zhao; Emily E Lewis; Lu Wang; Jeffrey J Wing; Baskaran Sundaram; Ella A Kazerooni; W Joseph McCune; Mariana J Kaplan
Journal:  PLoS One       Date:  2012-05-14       Impact factor: 3.240

Review 4.  Imbalance between endothelial damage and repair: a gateway to cardiovascular disease in systemic lupus erythematosus.

Authors:  Anselm Mak; Nien Yee Kow
Journal:  Biomed Res Int       Date:  2014-03-26       Impact factor: 3.411

Review 5.  Immunity and early atherosclerosis in the course of systemic lupus erythematosus, mixed connective tissue disease and antiphospholipid syndrome.

Authors:  Ewa Haładyj; Agnieszka Paradowska-Gorycka; Anna Felis-Giemza; Marzena Olesińska
Journal:  Reumatologia       Date:  2016-10-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.